Beyond Potency: Emerging Determinants and Optimization Strategies Enhancing Therapeutic Efficacy of Adult Stem Cells
Advanced Science · 2026-07 · 13 (40)
DOI: 10.1002/advs.76207 ↗At a glance
Übersichtsarbeit in Advanced Science, published online on 2026-06-19. Written by Soo-Rim Kim and 2 co-authors. Institution: Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, Republic of Korea. Major MEDLINE topics: Adult Stem Cells, Tissue Engineering, Stem Cell Transplantation. 156 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Research Foundation of Korea.
Abstract (original language)
Adult stem cell therapies are advancing, yet inconsistent clinical benefit indicates that in vitro potency only partially predicts in vivo performance. Framing efficacy through a systems lens, this review integrates three interlocking levers: (i) cell‐intrinsic programs (tissue imprint, transcriptional/epigenetic state, senescence and metabolic fitness), (ii) microenvironmental constraints and designable cues, and (iii) pre‐ and post‐delivery engineering interventions. We highlight how spatially organized biofabrication—especially 3D bioprinting that tunes geometry, stiffness, and factor presentation—converts a simple cell infusion into an architected niche that stabilizes survival, aligns angiogenesis, and accelerates functional integration. We also synthesize optimization levers spanning biochemical/cytokine licensing, hypoxic and mechanical conditioning, genetic/epigenetic programming, and extracellular‐vesicle–centered strategies; exemplar platforms show that 3D culture and printing can amplify small EV yield and pro‐regenerative content, translating to enhanced vascularization and repair in vivo. Translationally, early‐ and mid‐phase studies show adult stem cells —particularly MSCs—are broadly deliverable with acceptable safety; however, heterogeneity in sourcing, manufacture, dose/route, endpoints, and follow‐up undermines comparability, meta‐analysis, and payer confidence. We outline a path toward adequately powered, multicenter randomized trials under harmonized controls and mechanism‐linked potency assays with standardized clinical and biomarker endpoints. Finally, we examine the regulatory architecture: divergent definitions (manipulation, homologous use), GMP/GTP interpretations, and registry opacity enable uneven evidentiary thresholds and, at times, unregulated offerings—conditions that demand convergence on technical standards, explicit oversight transparency, and risk‐based enforcement. Throughout, mesenchymal stem/stromal cells (MSCs) serve as the principal exemplar of adult stem cells, with other adult stem cell populations cited to show that these principles generalize across cell types.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, Republic of Korea.
- Department of Molecular Medicine, School of Medicine, Gachon University, Incheon, Republic of Korea.
- Department of Microbiology, College of Medicine, Gachon University, Incheon, Republic of Korea.
- Division of Science Education, Kangwon National University, Chuncheon, Republic of Korea.
ORCID profiles: Hwa-Yong Lee
Funding
- National Research Foundation of Korea
Cite
APA
Kim, S. R., Jung, Y. J., & Lee, H. Y. (2026). Beyond Potency: Emerging Determinants and Optimization Strategies Enhancing Therapeutic Efficacy of Adult Stem Cells. Advanced Science, 13(40). https://doi.org/10.1002/advs.76207
Vancouver
Kim SR, Jung YJ, Lee HY. Beyond Potency: Emerging Determinants and Optimization Strategies Enhancing Therapeutic Efficacy of Adult Stem Cells. Advanced Science. 2026;13(40). doi:10.1002/advs.76207
BibTeX
@article{Kim2026,
author = {Kim, Soo-Rim and Jung, Yun Jae and Lee, Hwa-Yong},
title = {Beyond Potency: Emerging Determinants and Optimization Strategies Enhancing Therapeutic Efficacy of Adult Stem Cells},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {40},
doi = {10.1002/advs.76207}
}
EUVIMED